A Multicenter Real World Study of Kanglaite for Cancer Cachexia
Safety and Effectiveness of Kanglaite Injection/Capsules for Treatment of Cancer Cachexia: A Prospective, Multicenter Real World Study of a Large Cohort of Chinese Patients
Sponsor: LinkDoc Technology (Beijing) Co. Ltd.
A observational or N/A phase clinical study on Cancer Cachexia, this trial is ongoing. The trial is conducted by LinkDoc Technology (Beijing) Co. Ltd. and has accumulated 5 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Study Description(click to expand)This is a large national-based prospective, multi-center real-world observational study. Cancer cachexia patients scheduled for sequential treatment with Kanglaite injection and capsule between August 2018 and March 2020 at 640 participating hospitals will be recruited to evaluate the effectiveness and safety of Kanglaite.
This is a large national-based prospective, multi-center real-world observational study. Cancer cachexia patients scheduled for sequential treatment with Kanglaite injection and capsule between August 2018 and March 2020 at 640 participating hospitals will be recruited to evaluate the effectiveness and safety of Kanglaite.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status
-
Sep 2020 — Jan 2021 [monthly]
Unknown Status
Status: Not Yet Recruiting → Unknown Status
-
Sep 2018 — Sep 2020 [monthly]
Not Yet Recruiting
First recorded
Aug 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- LinkDoc Technology (Beijing) Co. Ltd.
- NanJing PLA 81 Hospital
- Zhejiang Kanglaite Pharmaceutical Co.Ltd
For direct contact, visit the study record on ClinicalTrials.gov .